FDA Adapts Drug Development Tool Procedures to Adopt Alzheimer’s Simulation Tool
This article was originally published in RPM Report
FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.
You may also be interested in...
As FDA gains experience with its new Drug Development Tool qualification process, the agency has found that a narrowly defined patient population and condition-specific measures are preferable.
COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process
FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.
White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.